Can levofloxacin (Levaquin) be used to treat Acinetobacter baumannii infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Levofloxacin (Levaquin) Should NOT Be Used for Acinetobacter baumannii Infections

Levofloxacin is not recommended for treating Acinetobacter baumannii infections due to lack of FDA approval for this indication, high resistance rates, and availability of superior alternatives with better clinical outcomes.

FDA-Approved Indications

The FDA label for levofloxacin does not include Acinetobacter baumannii among its approved pathogens for any indication 111. The drug is approved for nosocomial pneumonia caused by specific organisms (methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae), but A. baumannii is conspicuously absent from this list.

Guideline-Based Treatment Recommendations

For Carbapenem-Susceptible A. baumannii:

  • Carbapenems (imipenem or meropenem) are the drugs of choice in areas with low carbapenem resistance rates 222
  • Levofloxacin is not mentioned as a treatment option in current guidelines

For Carbapenem-Resistant A. baumannii (CRAB):

The 2015 ICU Task Force guidelines establish a clear hierarchy 2222:

  1. Polymyxins (colistin or polymyxin B) - suggested as part of empirical treatment for suspected CRAB
  2. Sulbactam (9-12 g/day in 3 doses) - may be preferable to colistin when MIC ≤4 mg/L due to better safety profile 222
  3. Tigecycline - not recommended as monotherapy 22

Fluoroquinolones like levofloxacin are not recommended in any guideline-based treatment algorithm for A. baumannii.

Clinical Evidence Against Levofloxacin Use

Resistance Patterns:

  • Research shows A. baumannii exhibits significant resistance to fluoroquinolones 34
  • In one study of nosocomial isolates, only 45% of non-pandrug-resistant A. baumannii were sensitive to levofloxacin, while all pandrug-resistant strains were completely resistant 4
  • Outbreak-related strains demonstrate significantly higher resistance to fluoroquinolones compared to sporadic strains 3

Comparative Efficacy:

The 2022 ESCMID guidelines demonstrate that when comparing treatment options for CRAB 5:

  • Ampicillin-sulbactam showed superior outcomes compared to polymyxins in multiple studies
  • One RCT showed 28-day mortality of 9/11 (82%) with colistin versus 5/12 (42%) with ampicillin-sulbactam when both were combined with high-dose levofloxacin 5
  • This suggests levofloxacin's contribution was insufficient to overcome the inherent resistance

When Levofloxacin Might Have Limited Adjunctive Role

The only scenario where levofloxacin appears in the literature is as a combination partner with more active agents:

  • One study used high-dose levofloxacin combined with either colistin or ampicillin-sulbactam for CRAB VAP 5
  • However, the ampicillin-sulbactam combination still outperformed the colistin combination, suggesting the primary activity came from the beta-lactam, not the fluoroquinolone

Research on synergy testing shows:

  • Colistin + levofloxacin demonstrated partial synergism in only 40% of MDR A. baumannii isolates 6
  • Colistin + meropenem showed better synergy (60% of isolates) 6

Critical Pitfalls to Avoid

  1. Do not use levofloxacin monotherapy - This will lead to treatment failure and potentially worsen resistance
  2. Do not assume fluoroquinolone activity - Always obtain susceptibility testing; resistance rates are prohibitively high
  3. Do not delay appropriate therapy - Using levofloxacin empirically while awaiting cultures wastes critical time when mortality is time-dependent
  4. Do not ignore local resistance patterns - Even if historical data suggested activity, current A. baumannii strains demonstrate extensive fluoroquinolone resistance

Recommended Approach

For suspected A. baumannii infection:

  • Empirical coverage: Polymyxin-based regimen if high suspicion for CRAB 22
  • Directed therapy (carbapenem-susceptible): Imipenem 0.5-1 g q6h or meropenem 2 g q8h 22
  • Directed therapy (CRAB with sulbactam MIC ≤4 mg/L): Sulbactam 9-12 g/day in 3 doses 22
  • Directed therapy (CRAB, sulbactam-resistant): Colistin 9 million IU/day (after 6-9 million IU loading dose) 22

Never include levofloxacin as a primary or sole agent for A. baumannii infections. The combination of lack of FDA approval, high resistance rates, and availability of superior alternatives makes this an inappropriate choice that could compromise patient outcomes.

References

Related Questions

In a patient with dysuria, a negative urinalysis, and a urine culture growing 35,000 CFU/mL Acinetobacter (baumannii), who is taking dapagliflozin (Farxiga), how should the infection be treated?
What is the appropriate levofloxacin dosing for Acinetobacter baumannii infections in adults and children, including adjustments for renal impairment and infection severity?
When Acinetobacter baumannii is isolated from blood, should an infectious disease consultation be obtained and is meropenem 1 g every 8 hours an appropriate initial therapy?
Is aztreonam appropriate for treating carbapenem‑resistant Acinetobacter baumannii (CRAB) infections, and what is the recommended dosing regimen?
What is the recommended ampicillin‑sulbactam dosing for carbapenem‑resistant Acinetobacter baumannii (CRAB) infection?
How should granuloma annulare be managed in a patient with few, asymptomatic, non‑cosmetically concerning lesions?
What is the recommended management for a posterior medial mid‑shaft tibial stress fracture in an 18‑year‑old male?
What is a burst of prednisone?
Is it safe for a patient who uses cannabis and is just beginning a new medication to attend a concert?
Is it safe for a patient who uses cannabis to start Concerta (methylphenidate), or should they stop cannabis use before beginning the medication?
What are the dosing guidelines, contraindications, and safety considerations for using lidocaine as a local anesthetic?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.